Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2010
06/23/2010CN101747321A Indole-3-benzylamine derivative, preparation method and application
06/23/2010CN101747282A Phenyl pyrimidone compounds, pharmaceutical compositions and preparation methods and uses thereof
06/23/2010CN101747253A Trisubstituted chiral lactam derivative and preparation method and application thereof
06/23/2010CN101747226A N-oxalic acid acyl amino acid derivatives and N-oxalic acid acyl dipeptide derivatives as well as applications thereof in preparation of consciousness-promoted drugs
06/23/2010CN101745083A Sweating decoction of cassia twig and purple perilla
06/23/2010CN101744974A Traditional Chinese medicine for treating Behcet's diseases
06/23/2010CN101744942A Juvenile promotive raising agent
06/23/2010CN101744841A Collins john kevin; o'sullivan gerald christopher; o'mahony liam; shanahan fergus
06/23/2010CN101744837A Preparation method for sinonovacula constricta enzymolysis liquid with diversified bioactivities
06/23/2010CN101744798A Calcium-containing citrate concentrated anticoagulant hemodialysis solution
06/23/2010CN101744487A Chinese medicinal tea health care pillow
06/23/2010CN101322693B Carthamus tinctorius yellow colour injection and preparation technique thereof
06/23/2010CN101268862B Method for preparing gingkgo health care cigarette
06/23/2010CN101152500B Chinese medicine for curing appendicitis and method for preparing the same
06/23/2010CN101087584B Use of a compound capable of increasing glutathione level in melanocytes for treating canities
06/23/2010CN101007815B Pyrrolehexa-heterocyclic compound and pharmaceutical use thereof
06/22/2010US7741452 produced by introducing amino acid mutation(s) so that no glycosylation take place at at least one glycosylation site of hepatocyte growth factor; more stable in the blood circulation
06/22/2010US7741447 Antibody against tumor specific antigen as target
06/22/2010US7741445 Multidrug resistance proteins; xenobiotic transporters; counteracting the mechanism of drug resistance so to provide a longer and more effective course of chemotherapeutic drug treatment for cancer patients
06/22/2010US7741440 Apoptin-associating protein
06/22/2010US7741434 High-affinity antagonists of ELR-CXC chemokines
06/22/2010US7741349 Neuroprotectants; treatment of neuropathies resulting from chemtherapeutic agents used in the treatment of HIV and proliferative disease such as cancer and treatment of inflammatory diseases; neurodegenerative diseases; enzyme inhibitors for seine/threonine kinases, phosphatases; Alzheimer'
06/22/2010US7741346 Vision defects; anticancer agents; antitumor agents
06/22/2010US7741343 6H-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
06/22/2010US7741340 Hydroxy piperidine derivatives to treat gaucher disease
06/22/2010US7741339 Fab I inhibitors
06/22/2010US7741335 administering nontoxic, preferential and potent c-kit ligand inhibitors such as imatinib, to humans for treatment of inflammatory diseases such as rheumatoid arthritis
06/22/2010US7741329 such as 1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-quinolin-2-yl-methanone, used as human orexin receptor antagonist, for the treatment of obesity and insomnia
06/22/2010US7741328 Treating inflammatory diseases such as rheumatoid arthritis, multiple sclerosis or Crohn's disease; Very Late Antigen-4 (VLA-4), also called alpha 4 beta 1 integrin; N-(sulfonamido-substituted pyrimidyl, pyridyl or pyrazyl)-L-4-(N,N-dimethylcarbamyloxy)phenylalanine compounds
06/22/2010US7741312 Benzylaminosulfonic Acid or portion or analogue linked to a carbohydrate or glycomimetic for modulating processes mediated by selectin binding such as autoimmune and inflammatory diseases, shock and reperfusion injuries
06/22/2010US7741282 Apo2L/TRAIL formulations including lyophilized and crystal compositions; may be used in inducing apoptosis in mammalian cells including cancer cells by exposing mammalian cells to an effective amount of an Apo-2 ligand formulation described herein
06/22/2010US7741274 Increasing hematopoiesis; treating glucosuria, hyperglycemia and diabetes; thrombocytopenia
06/22/2010US7741078 Heparin-binding protein modified with heparan sulfate sugar chains, process for producing the same and pharmaceutical compositions containing the same
06/22/2010US7741030 detecting whether CpG sequences in a region from base 374 to base 592 in a DR3 gene promoter region obtained from synovial cells or synovial infiltrating lymphocytes of the human subject are methylated or not
06/22/2010US7740841 Therapeutic method for reducing angiogenesis
06/22/2010US7740834 Murine zcytor17 ligand polypeptides
06/22/2010US7740831 Compositions for potentiating glutathione
06/22/2010US7740830 Imaging, diagnosis and treatment of disease
06/22/2010CA2552218C Left-side glucose lipid a analogue
06/22/2010CA2500575C New derivatives of 4-oxo-4,6,7,8-tetrhydro-pyrrolo[1,2-a]pyrazine-6-carbonxamides, their preparation process and the pharmaceutical compositions that contain them
06/22/2010CA2492161C New derivatives of fluorinated benzothiadiazines, the process for preparing them and the pharmaceutical compounds that contain them
06/22/2010CA2485479C New 2-(.alpha.-hydroxypentyl) benzoates, their preparations and their uses
06/22/2010CA2480409C Novel pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
06/22/2010CA2448741C Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
06/22/2010CA2444198C Nociceptin analogs
06/22/2010CA2443938C Spiroindene and spiroindane compounds as opioid ligands useful for treating pain
06/22/2010CA2439430C Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity
06/22/2010CA2420996C Substituted heterocyclic compounds for treating multidrug resistance
06/22/2010CA2412718C Viral polymerase inhibitors
06/22/2010CA2411716C 1,3,8-triaza-spiro [4.5] decan derivatives
06/22/2010CA2410408C 2-aminoalkylthieno[2,3-d]pyrimidines
06/22/2010CA2406177C 8.beta.-hydrocarbyl-substituted estratrienes as selectively active estrogens
06/22/2010CA2401655C Cardioprotective phosphonates and malonates
06/22/2010CA2395493C Hyaluronic acid in the treatment of cancer
06/22/2010CA2389553C Heteroaryl-diazabicycloalkanes
06/22/2010CA2382355C Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
06/22/2010CA2374346C Inhibitors of memapsin 2 and use thereof
06/22/2010CA2353905C Chemotherapeutic composition and method
06/22/2010CA2323073C Uses for human non-autologous mesenchymal stem cells
06/22/2010CA2315715C Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
06/22/2010CA2295577C Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumors originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma
06/22/2010CA2233550C Symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
06/22/2010CA2216963C Tie-2 ligands, methods of making and uses thereof
06/22/2010CA2211413C Human dnase i variants
06/22/2010CA2190943C Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
06/22/2010CA2175893C Protein tyrosine kinases named rse
06/17/2010WO2010067888A1 Dihydropyrimidopyrimidine derivatives
06/17/2010WO2010067886A1 Dihydropyrimidopyrimidine derivative
06/17/2010WO2010067882A1 Pharmaceutical composition for treatment of cancer and asthma
06/17/2010WO2010067594A1 Hexahydropyrroloindole derivative
06/17/2010WO2010066852A1 Composition comprising isoflavones
06/17/2010WO2010066815A2 Encapsulating system for cest imaging with chelate q greater than or equal to 2
06/17/2010WO2010044981A3 Benzoquinoline inhibitors of vesicular monoamine transporter 2
06/17/2010WO2010033598A3 System and method for utilizing microbubbles and liposomes as viral sequestering agents
06/17/2010US20100152831 Implantable Medical Devices Having Multiblock Copolymers
06/17/2010US20100152446 Piperidine Derivatives
06/17/2010US20100152442 4-anilino quinazoline derivatives as antiproliferative agents
06/17/2010US20100152303 Agents and method for increasing brain chaperonin levels
06/17/2010US20100152293 Use of polyunsaturated ketones for the treatment of psoriasis
06/17/2010US20100152288 NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF
06/17/2010US20100152282 Use of double stranded rna hairpin duplexes in gene silencing
06/17/2010US20100152280 Modulation of sid-1 expression
06/17/2010US20100152250 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
06/17/2010US20100152211 Inhibitors of human phosphatidylinositol 3-kinase delta
06/17/2010US20100152167 Pyrimidine derivatives
06/17/2010US20100152133 Use of chitosans to increase nail growth rate
06/17/2010US20100152127 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
06/17/2010US20100152120 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
06/17/2010US20100152115 Detection of physiologically acceptable polymer molecules using near infrared spectroscopy
06/17/2010US20100152105 Use of rapamycin derivatives in chronic rejection
06/17/2010US20100152095 Wound healing
06/17/2010US20100151589 Glycoproteins Having Lipid Mobilising Properties and Therapeutic Applications Thereof
06/17/2010US20100151507 Cavity Induced Allosteric Modification Of Intermolecular Interactions And Methods Of Identifying Compounds That Effect The Same
06/17/2010US20100151458 Oligoribonucleotides and ribonucleases for cleaving rna
06/17/2010US20100151036 Multiphase drug delivery system
06/17/2010US20100151023 Time delayed release mechanism for energizing composition and method of use
06/17/2010US20100151005 Targeted carriers for intracellular drug delivery
06/17/2010US20100150983 Outer layer having entanglement of hydrophobic polymer host and hydrophilic polymer guest
06/17/2010US20100150982 Deposition of nanocrystalline calcite on surfaces by a tissue and cellular biomineralization
06/17/2010US20100150861 Compostions with enhanced bioavailability and fast acting inhibitor or gastric acid secretion
1 ... 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 ... 1564